{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:58:42Z","timestamp":1790834322912,"version":"4.1.0"},"reference-count":107,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a devastating disease with an incidence that progressively increases with advancing age. Currently, only \u223c40% of younger and 10% of older adults are long-term survivors. If untreated, the overall prognosis of AML remains dismal. Initiation of therapy at diagnosis is usually urgent. Barriers to successful therapy for AML are the attendant toxicities directly related to chemotherapy or those associated with inevitable aplasia. Organ dysfunction often further complicates such toxicities and may even be prohibitive. There are few guidelines to manage such patients and the fear of crossing the medico-legal abyss may dominate. Such clinical scenarios provide particular challenges and require experience for optimal management. Herein, we discuss select examples of common pretreatment comorbidities, including cardiomyopathy, ischemic heart disease; chronic renal failure, with and without dialysis; hepatitis and cirrhosis; chronic pulmonary insufficiency; and cerebral vascular disease. These comorbidities usually render patients ineligible for clinical trials and enormous uncertainty regarding management reigns, often to the point of withholding definitive therapy. The scenarios described herein emphasize that with appropriate subspecialty support, many AML patients with comorbidities can undergo therapy with curative intent and achieve successful long-term outcome.<\/jats:p>","DOI":"10.1182\/blood-2016-01-635060","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T02:49:09Z","timestamp":1464403749000},"page":"488-496","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["How I treat acute myeloid leukemia presenting with preexisting comorbidities"],"prefix":"10.1182","volume":"128","author":[{"given":"Yishai","family":"Ofran","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel;"},{"name":"Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2019111906092303500_B1","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1200\/JCO.2003.03.186","article-title":"Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials.","volume":"21","author":"Mengis","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111906092303500_B2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.15420\/ecr.2012.8.2.108","article-title":"Measuring left ventricular ejection fraction \u2013 techniques and potential pitfalls.","volume":"8","author":"Foley","year":"2012","journal-title":"Eur Cardiol"},{"issue":"2","key":"2019111906092303500_B3","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijcard.2013.03.133","article-title":"Cardioncology: state of the heart.","volume":"168","author":"Todaro","year":"2013","journal-title":"Int J Cardiol"},{"issue":"5","key":"2019111906092303500_B4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111906092303500_B5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","article-title":"A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.","volume":"103","author":"Rowe","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111906092303500_B6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr346","article-title":"Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.","volume":"23","author":"Brunnberg","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111906092303500_B7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.leukres.2007.06.015","article-title":"Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.","volume":"32","author":"Kessler","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"2019111906092303500_B8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.blre.2015.11.001","article-title":"Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart\u2019s content.","volume":"30","author":"Oliveira","year":"2016","journal-title":"Blood Rev"},{"issue":"1","key":"2019111906092303500_B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"2019111906092303500_B10","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2019111906092303500_B11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111906092303500_B12","first-page":"194","article-title":"Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.","volume":"52","author":"Alderton","year":"1992","journal-title":"Cancer Res"},{"issue":"16","key":"2019111906092303500_B13","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"2019111906092303500_B14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2019111906092303500_B15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"issue":"3","key":"2019111906092303500_B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/cncr.22434","article-title":"Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes.","volume":"109","author":"Sarkiss","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2019111906092303500_B17","first-page":"336","article-title":"Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.","volume":"37","author":"Yusuf","year":"2010","journal-title":"Tex Heart Inst J"},{"issue":"11","key":"2019111906092303500_B18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.7326\/0003-4819-159-11-201312030-00009","article-title":"Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.","volume":"159","author":"Qaseem","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111906092303500_B19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"key":"2019111906092303500_B20","first-page":"CD005008","article-title":"Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.","volume":"3","author":"van Dalen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2019111906092303500_B21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM199207163270308","article-title":"The use of aspirin in ischemic heart disease.","volume":"327","author":"Willard","year":"1992","journal-title":"N Engl J Med"},{"issue":"8719","key":"2019111906092303500_B22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.","volume":"336","author":"The RISC Group","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"2019111906092303500_B23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2019111906092303500_B24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","article-title":"Hyperleukocytosis, leukostasis and leukapheresis: practice management.","volume":"26","author":"Ganzel","year":"2012","journal-title":"Blood Rev"},{"issue":"16","key":"2019111906092303500_B25","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111906092303500_B26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"2019111906092303500_B27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-12-415948-8.00015-5","article-title":"Pharmacokinetics of anti-cancer chemotherapy in renal insufficiency and dialysis.","volume-title":"Renal Disease in Cancer Patients","author":"Fissell","year":"2014"},{"issue":"10","key":"2019111906092303500_B28","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.1989.7.10.1563","article-title":"The association between high-dose cytarabine neurotoxicity and renal insufficiency.","volume":"7","author":"Damon","year":"1989","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111906092303500_B29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","article-title":"Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.","volume":"21","author":"Kintzel","year":"1995","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2019111906092303500_B30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","article-title":"The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.","volume":"135","author":"Appelbaum","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111906092303500_B31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF00686499","article-title":"Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.","volume":"33","author":"Yoshida","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2019111906092303500_B32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur J Cancer"},{"issue":"3","key":"2019111906092303500_B33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/era.11.2","article-title":"Management of hematological malignancies in patients affected by renal failure.","volume":"11","author":"Niscola","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"2019111906092303500_B34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","article-title":"Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.","volume":"21","author":"Janus","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111906092303500_B35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00174156","article-title":"Pharmacology of mitoxantrone: mode of action and pharmacokinetics.","volume":"3","author":"Alberts","year":"1985","journal-title":"Invest New Drugs"},{"key":"2019111906092303500_B36"},{"issue":"suppl","key":"2019111906092303500_B37","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1007\/BF00684868","article-title":"Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.","volume":"34","author":"Stewart","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2019111906092303500_B38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology.","volume":"169","author":"Jones","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111906092303500_B39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/ndt\/gfv007","article-title":"Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry.","volume":"30","author":"Vogelzang","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2019111906092303500_B40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/cid\/cit546","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among patients on chronic dialysis in the United States, 2005-2011.","volume":"57","author":"Nguyen","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1-4","key":"2019111906092303500_B41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000360034","article-title":"UK Renal Registry 16th annual report: chapter 15 epidemiology of reported infections amongst patients receiving dialysis for established renal Failure in England from May 2011 to April 2012: a joint report from Public Health England and the UK Renal Registry.","volume":"125","author":"Crowley","year":"2013","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"2019111906092303500_B42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.ajkd.2014.05.016","article-title":"Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance.","volume":"65","author":"Zacharioudakis","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2019111906092303500_B43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0002-9343(00)00371-5","article-title":"A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients.","volume":"108","author":"Beddhu","year":"2000","journal-title":"Am J Med"},{"issue":"1","key":"2019111906092303500_B44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2215\/CJN.03860609","article-title":"Predicting six-month mortality for patients who are on maintenance hemodialysis.","volume":"5","author":"Cohen","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019111906092303500_B45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/asheducation-2009.1.396","article-title":"Optimal induction and post-remission therapy for AML in first remission.","volume":"2009","author":"Rowe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2019111906092303500_B46","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1200\/JCO.1992.10.6.948","article-title":"Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.","volume":"10","author":"Rubin","year":"1992","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111906092303500_B47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bmt.1701380","article-title":"Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis.","volume":"22","author":"Bischoff","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111906092303500_B48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.bmt.1701646","article-title":"Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.","volume":"23","author":"Perry","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111906092303500_B49","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/hep.27056","article-title":"HBV reactivation in immunosuppressed patients: prevention or containment?","volume":"59","author":"Ludwig","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"2019111906092303500_B50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.","volume":"22","author":"Yeo","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111906092303500_B51","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/annonc\/mdp230","article-title":"Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier.","volume":"20","author":"Fukushima","year":"2009","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111906092303500_B52","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.","volume":"90","author":"Yeo","year":"2004","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"2019111906092303500_B53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.2010.02396.x","article-title":"The difficulties of managing severe hepatitis B virus reactivation.","volume":"31","author":"Roche","year":"2011","journal-title":"Liver Int"},{"key":"2019111906092303500_B54","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy [published correction appears in Gastroenterology. 2015;148(2):455].","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"19","key":"2019111906092303500_B55","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":"American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.","volume":"28","author":"Artz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111906092303500_B56","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111906092303500_B57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cld.426","article-title":"Defining and grading HBV reactivation.","volume":"5","author":"Visram","year":"2015","journal-title":"Clin Liver Dis"},{"issue":"4","key":"2019111906092303500_B58","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jmv.24115","article-title":"Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection.","volume":"87","author":"Kamitsukasa","year":"2015","journal-title":"J Med Virol"},{"issue":"10","key":"2019111906092303500_B59","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2019111906092303500_B60","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.","volume":"9","author":"Torres","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111906092303500_B61","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at http:\/\/hcvguidelines.org\/. Accessed March 2016"},{"issue":"1","key":"2019111906092303500_B62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.dld.2011.07.016","article-title":"Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy.","volume":"44","author":"Coppola","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"22","key":"2019111906092303500_B63","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.3748\/wjg.v20.i22.6716","article-title":"Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.","volume":"20","author":"Yazici","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"8","key":"2019111906092303500_B64","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices.","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"2019111906092303500_B65"},{"key":"2019111906092303500_B66","first-page":"659","article-title":"Chemotherapeutic agents: idarubicin.","volume-title":"The Chemotherapy Source Book","author":"Haddadin","year":"2012","edition":"5th ed"},{"issue":"1","key":"2019111906092303500_B67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","article-title":"Hepatotoxicity of chemotherapy.","volume":"33","author":"Floyd","year":"2006","journal-title":"Semin Oncol"},{"issue":"3","key":"2019111906092303500_B68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/106002809202600311","article-title":"The effects of impaired liver function on the elimination of antineoplastic agents.","volume":"26","author":"Koren","year":"1992","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2019111906092303500_B69","first-page":"1059","article-title":"Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.","volume":"70","author":"Donehower","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"2019111906092303500_B70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy.","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"issue":"3","key":"2019111906092303500_B71","first-page":"303","article-title":"Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).","volume":"20","author":"Bellet","year":"1973","journal-title":"Neoplasma"},{"issue":"1","key":"2019111906092303500_B72","first-page":"55","article-title":"Phase II study of 5-azacytidine in solid tumors.","volume":"61","author":"Weiss","year":"1977","journal-title":"Cancer Treat Rep"},{"issue":"18","key":"2019111906092303500_B73","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2169\/internalmedicine.48.2358","article-title":"Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney.","volume":"48","author":"Yamane","year":"2009","journal-title":"Intern Med"},{"issue":"9","key":"2019111906092303500_B74","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1478-3231.2008.01745.x","article-title":"All-trans-retinoic acid ameliorates carbon tetrachloride-induced liver fibrosis in mice through modulating cytokine production.","volume":"28","author":"Hisamori","year":"2008","journal-title":"Liver Int"},{"issue":"1","key":"2019111906092303500_B75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbadis.2006.08.009","article-title":"Effects of retinoic acid on the development of liver fibrosis produced by carbon tetrachloride in mice.","volume":"1772","author":"Wang","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2019111906092303500_B76","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2007-06-095844","article-title":"Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111906092303500_B77","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cncr.24711","article-title":"Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.","volume":"116","author":"Al Ameri","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"2019111906092303500_B78","first-page":"103","article-title":"Severe sepsis and septic shock in patients with pre-existing non-cardiac pulmonary hypertension: contemporary management and outcomes.","volume":"15","author":"Tsapenko","year":"2013","journal-title":"Crit Care Resusc"},{"issue":"8","key":"2019111906092303500_B79","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2019111906092303500_B80","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"2019111906092303500_B81","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1002\/ajh.23764","article-title":"Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.","volume":"89","author":"Yamamoto","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111906092303500_B82","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111906092303500_B83","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.leukres.2011.11.021","article-title":"The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients.","volume":"36","author":"Savic","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"2019111906092303500_B84","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111906092303500_B85","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111906092303500_B86","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.","volume":"97","author":"L\u00fcbbert","year":"2012","journal-title":"Haematologica"},{"issue":"24","key":"2019111906092303500_B87","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.","volume":"120","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111906092303500_B88","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2012.01.009","article-title":"Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.","volume":"18","author":"Gerds","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111906092303500_B89","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.leukres.2013.02.014","article-title":"Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS\/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).","volume":"37","author":"Bally","year":"2013","journal-title":"Leuk Res"},{"issue":"5","key":"2019111906092303500_B90","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ccr3.212","article-title":"Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah\u2019s Witness with acute monocytic leukemia.","volume":"3","author":"Garelius","year":"2015","journal-title":"Clin Case Rep"},{"issue":"1","key":"2019111906092303500_B91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000368711","article-title":"Azacitidine pre-treatment followed by reduced-intensity stem cell transplantation in patients with higher-risk myelodysplastic syndrome.","volume":"134","author":"Ahn","year":"2015","journal-title":"Acta Haematol"},{"issue":"1","key":"2019111906092303500_B92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbmt.2009.08.016","article-title":"Lung function and long-term complications after allogeneic hematopoietic cell transplant.","volume":"16","author":"Walter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111906092303500_B93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.22183","article-title":"Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome.","volume":"87","author":"Pi\u00f1ana","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111906092303500_B94","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2014.113399","article-title":"Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).","volume":"100","author":"Caira","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2019111906092303500_B95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/01.STR.0000106480.76217.6F","article-title":"Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial.","volume":"35","author":"Chapman","year":"2004","journal-title":"Stroke"},{"issue":"4","key":"2019111906092303500_B96","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1163\/15685590160141387","article-title":"Co-existence of thrombocytopenia and hyperleukocytosis (\u2018critical period\u2019) as a risk factor of haemorrhage into the central nervous system in patients with acute leukaemias.","volume":"31","author":"Nowacki","year":"2002","journal-title":"Haematologia (Budap)"},{"issue":"5","key":"2019111906092303500_B97","first-page":"622","article-title":"Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients.","volume":"89","author":"Kim","year":"2004","journal-title":"Haematologica"},{"issue":"6","key":"2019111906092303500_B98","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdn755","article-title":"Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia.","volume":"20","author":"Chen","year":"2009","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111906092303500_B99","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood-2012-04-424440","article-title":"How I treat hematologic emergencies in adults with acute leukemia.","volume":"120","author":"Zuckerman","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2019111906092303500_B100","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1161\/CIRCULATIONAHA.107.183689","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association\/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group.","volume":"116","author":"Broderick","year":"2007","journal-title":"Circulation"},{"issue":"13","key":"2019111906092303500_B101","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia.","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111906092303500_B102","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in N Engl J Med. 2010;362(12):1155].","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111906092303500_B103","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.22031","article-title":"Prediction model for mortality after intracranial hemorrhage in patients with leukemia.","volume":"86","author":"Dayyani","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111906092303500_B104","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.1988.6.3.495","article-title":"High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia.","volume":"6","author":"Cassileth","year":"1988","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111906092303500_B105","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3109\/10428194.2014.953148","article-title":"Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.","volume":"56","author":"Rozovski","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2019111906092303500_B106","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12885-015-1376-9","article-title":"Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults.","volume":"15","author":"Cheng","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"2019111906092303500_B107","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.1995.tb08358.x","article-title":"Unexpected high incidence of intracranial subdural haematoma during intensive chemotherapy for acute myeloid leukaemia with a monoblastic component.","volume":"89","author":"Jourdan","year":"1995","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/4\/488\/1397614\/488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/4\/488\/1397614\/488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:00:39Z","timestamp":1718604039000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/4\/488\/35392\/How-I-treat-acute-myeloid-leukemia-presenting-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-01-635060","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}